Translating SLE Efficacy Biomarkers from Mice to Humans
You are here: Home » News » 03.Drug Development Perspectives » Translating SLE Efficacy Biomarkers from Mice to Humans

Translating SLE Efficacy Biomarkers from Mice to Humans

Views: 0     Author: Site Editor     Publish Time: 2026-11-16      Origin: Site

Inquire

wechat sharing button
line sharing button
twitter sharing button
facebook sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

HKeyBio Industry Commentary

Translating SLE Efficacy Biomarkers from Mice to Humans

Translational Medicine Series 02

Originally published in Chinese on June 4, 2026. This commentary reflects information available as of June 4, 2026.

HKeyBio’s take. Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production and type I interferon (IFN-I) pathway activation. How can developers connect a drug effect observed in mice to what matters in patients? A mechanism-aligned set of disease models and a biomarker strategy that links target engagement, pathway modulation and organ-level outcomes can make that evidence more informative.

Reading Guide

01  Where rodent models fall short in SLE efficacy assessment

02  Key biomarkers for SLE efficacy assessment

03  How nonhuman primate models can bridge selected translational questions

04  How to build a reliable chain of evidence

SLE prevalence varies widely across populations and study designs [1]. One global modeling study estimated that 3.41 million people were living with SLE, or 43.7 per 100,000 [2]. The frequently cited estimate of five million refers to people living with some form of lupus worldwide [3]. In a nationwide study of urban China, the age- and sex-standardized SLE prevalence was 47.61 per 100,000 in 2017 (95% CI 41.77–53.83) [4].

Belimumab (2011) and anifrolumab (2021) were important U.S. milestones. By the time this article first appeared, the FDA had also approved obinutuzumab for adults with active lupus nephritis receiving standard therapy [5–7]. Translating preclinical activity into clinical benefit remains challenging. Rituximab did not meet the primary endpoints in EXPLORER, a phase II/III study in moderately to severely active SLE, or in LUNAR, a phase III study in proliferative lupus nephritis [8,9]. These trials illustrate why evidence of B-cell depletion must be interpreted alongside organ response and clinical outcomes.

01  Limitations of Rodent Models in SLE

Spontaneous MRL/lpr mice and models induced by pristane or Toll-like receptor 7 (TLR7) agonists remain important tools for early efficacy assessment and mechanistic research [10]. Yokogawa and colleagues showed that topical TLR7 agonists could induce systemic autoimmunity in wild-type mice, with anti-double-stranded DNA (anti-dsDNA) antibodies and involvement of multiple organs [11]. This established a useful model for studying how TLR7 signaling contributes to lupus-like disease.

Species differences matter when the clinical candidate is a highly specific antibody or a sequence-directed oligonucleotide. Mouse blood is generally lymphocyte-predominant, whereas human blood is generally neutrophil-predominant [12]. The difference can affect cytokine responses and the apparent drug effect on a given cell subset. Before choosing a species, confirm target expression and functional activity, including binding for antibodies and sequence compatibility for oligonucleotides. For rituximab, conventional wild-type mice cannot directly reproduce depletion via human CD20. A pharmacologically matched surrogate or a human-CD20 model can address a defined question. The available evidence does not establish mouse cross-reactivity as the cause of either clinical result.

Antibody pharmacokinetics (PK) can also diverge across species. Human and cynomolgus macaque (Macaca fascicularis) neonatal Fc receptor (FcRn) alpha chains share approximately 96% sequence identity. FcRn-mediated IgG recycling influences clearance, exposure and half-life, while binding properties, target-mediated clearance and antidrug antibodies can also shape those measurements [13]. For small molecules, cytochrome P450 expression, tissue distribution and catalytic activity can differ across species [14]. In the retrospective Olson survey, concordance with known human toxicities was 63% for nonrodents and 43% for rodents, rising to 71% when the two groups were considered together [15]. These rates describe the study dataset and the species groupings used.

For a human-specific candidate, a rodent efficacy result may tell us how a mechanism affects disease while leaving questions about the clinical molecule’s pharmacodynamics (PD) and biomarker response. Those questions should guide the next model choice.

Figure 1. TLR7 signaling and lupus-like inflammation. TLR7 in pDCs and B cells signals from endosomes. UVB is a tissue-stress input [11,16,17].

image.png

 Figure 2. Cross-species comparison of immune-cell composition, FcRn sequence identity and toxicity. The species-specific values in panel C are illustrative. The published Olson comparison reports pooled true-positive concordance [15].

image.png

02  Key Biomarkers for SLE Efficacy Assessment

Biomarkers can track disease activity and connect preclinical observations to clinical studies. The 2019 European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) criteria use ANA as an entry criterion and include anti-dsDNA, anti-Sm and low complement in the weighted classification domains [18]. Their value in classification is distinct from their role in assessing a treatment response.

2.1  Autoantibodies and Complement

Anti-dsDNA and ANA capture different aspects of lupus serology. Published reports have cited anti-dsDNA positivity of 70–98% in selected populations and sensitivity and specificity estimates of 57.3% and 97.4%, respectively, from other datasets [19]. These figures depend on assay, threshold and cohort. The ANA meta-analysis cited by the 2019 criteria found 97.8% sensitivity at a titer of at least 1:80 [18]. In mouse models induced with activated lymphocyte-derived DNA (ALD-DNA), declining anti-dsDNA or ANA titers may support a drug effect on B-cell activation or autoantibody production [20]. Pair titers with cell-level or tissue readouts to distinguish those mechanisms.

Low circulating C3 and C4 can reflect consumption during immune-complex-mediated activation of the classical complement pathway. One longitudinal study found hypocomplementemia in 67% of its SLE cohort over follow-up [21]. Low complement can accompany higher disease activity, and recovery may support a treatment response when consistent with renal or other clinical findings. Interpret complement trajectories in context, especially when using a disease activity index that already incorporates complement.

2.2  Cytokines and the Type I Interferon Signature

Heightened IFN-I signaling is a major feature of SLE. Approximately 60–80% of adults with active SLE have elevated expression of type I IFN-inducible genes [6,16,17]. Anifrolumab targets type I interferon receptor subunit 1 (IFNAR1). In a pooled analysis of the anifrolumab 300 mg and placebo groups in TULIP-1 and TULIP-2, 82.6% of 726 participants were IFN gene signature-high at baseline [22]. The signature supported trial stratification and assessment of pathway modulation. TULIP-2 assessed clinical efficacy through the week 52 BILAG-based Composite Lupus Assessment (BICLA) response [23].

In TLR7-driven models and patient studies, IFN-α, interferon-stimulated genes (ISGs), CXCL10 (IP-10) and CCL2 (MCP-1) can help characterize pathway activity [11,24]. A proteomic analysis of TULIP samples found reductions in CXCL10 and CCL2 with anifrolumab [24]. The findings support their value as exploratory PD markers. Standardize the sample type, timing and assay before comparing longitudinal results across models and patient cohorts. This is particularly useful for drugs directed at pDCs or TLR7/8/9 signaling.

2.3  Target Organ Injury in Lupus Nephritis

Renal involvement is a major cause of SLE morbidity. Estimates vary by cohort and how renal involvement is defined. An early Chinese SLE Treatment and Research Group (CSTAR) cohort included 849 patients with lupus nephritis among 2,104 participants (40.4%) [25]. Skin and mucosal manifestations are also common and warrant separate assessment when relevant to the candidate [16,25].

For the kidney, 24-hour urinary protein or a urine protein-to-creatinine ratio, serum creatinine and renal histology provide clinically anchored readouts. Animal studies can also measure glomerular IgG, IgA, IgM and C3 deposition and assess histologic activity and chronicity using scoring appropriate to the model. A historical meta-analysis found that 15-year kidney failure risk varied by disease class, region and treatment era, reaching 44% for class IV nephritis in studies from the 2000s [26]. That burden underlines the value of testing whether pathway modulation is accompanied by organ protection.

03  Nonhuman Primate Models as a Translational Bridge

Nonhuman primate (NHP) studies in cynomolgus macaques can help link exposure, functional target engagement and tissue-level PD when a candidate is active in that species. Qu and colleagues built a single-cell atlas of chromatin accessibility and gene expression across macaque tissues [27]. Cross-species comparisons can identify conserved features as well as differences. The relevant cell compartment and functional response still need to be confirmed for each program.

The HKeyBio SLE and CLE Model Portfolio

HKeyBio was founded in 2017. At the time of the original article, the company reported that autoimmune and allergy programs accounted for over 95% of its business, and that it had completed more than 1,000 projects, supported more than 500 investigational new drug (IND) applications and served more than 1,000 clients. Its research operations use Institutional Animal Care and Use Committee (IACUC) review and include ISO 9001 certification and AAALAC accreditation. HKEY-NHP-MATRIX 2.0 covers more than 30 autoimmune and allergic disease indications, and HKEY-AIDMD 3.0 contains more than 10,000 in vivo experimental records, according to HKeyBio.

TLR7 agonist-induced cynomolgus SLE model. HKeyBio uses topical imiquimod three times weekly over 10 weeks. In its model characterization, anti-dsDNA titers increased over time, circulating IFN-α rose, and ISG expression increased in peripheral blood mononuclear cells (PBMCs). Renal hematoxylin and eosin (H&E) staining and histology scores indicated glomerular inflammation and changes consistent with possible immune-complex deposition. Dedicated immunostaining can confirm deposition. These readouts allow parallel assessment of systemic IFN pathway activity and renal pathology.

TLR7 agonist plus UVB cynomolgus CLE model. The six-week model combines TLR7 agonism with local UVB exposure to assess cutaneous lupus erythematosus (CLE) and systemic immune activity in the same study. Readouts include clinical skin scores, skin IFN-α expression, skin histology, longitudinal anti-dsDNA titers, skin RNA sequencing and immune-cell clustering.

Takahama and colleagues profiled the oral TLR7 agonist SA-5 in cynomolgus macaques and measured exposure and IFN-related PD responses [28]. This provides evidence of measurable macaque pathway engagement. Brown and colleagues showed that a gain-of-function TLR7 variant can cause human lupus, supporting the rationale for TLR7-driven models and therapies directed at this pathway [29]. These studies address pathway biology and model rationale. Clinical efficacy prediction requires evidence specific to the drug and indication.

Cynomolgus studies can bring PK, serial PD markers and dose–response data into one design. The strength of the bridge depends on the molecule’s FcRn interactions, target-mediated disposition and the relevance of its complement or effector-cell biology. Verify these functions directly when complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) is important to the mechanism.

Figure 3. HKeyBio SLE and CLE model matrix. The comparative scores in the lower panels are illustrative and have no stated scoring method.

image.png

 

04  How Can We Build a Reliable Chain of Evidence

HKeyBio’s proposed sequence starts with rodent screening, moves to an NHP study when it can answer a defined translational question, and then tests the relevance of those findings in patients. Each stage should connect a model to a biomarker and a development decision.

Figure 4. Staged biomarker strategy and supporting HKeyBio platforms.

image.png

 Table 1. Recommended models and core measurements by development stage.

image.png

 The mouse portfolio covers spontaneous, chemically induced, humanized and antigen- or apoptotic cell-induced models to support early screening across different targets. The model choice and assessment window should follow the mechanism and the tissue phenotype the program needs to test.

For NHP studies, HKEY-AIRx 1.0 integrates candidate-specific PK/PD with human data and mechanistic assumptions. Relevant inputs may include FcRn-mediated IgG disposition, complement activation and IFN-I pathway responses. The resulting models can support a proposed first-in-human starting dose and an exposure or dose range to explore, alongside safety and other inputs. HKEY-NHP-onChip 1.1 combines NHP-derived organoids with organ-on-chip systems to study candidate effects in target tissues in vitro.

HKeyBio also reports collaborations with Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and Shanxi Provincial People’s Hospital to advance translational research. A separate 2024 Frontiers in Immunology paper on IL-17A/IL-36 blockade reported HKeyBio and Weiyuan IACUC approval for animal work and listed separate approvals for cynomolgus PK and toxicology. Its accession, PRJNA1181153, documents that study [30]. Public evidence for the HKeyBio SLE and CLE models requires disease-specific data.

Anifrolumab illustrates how PD and clinical efficacy can be evaluated in the same program. IFN-driven gene expression helped quantify pathway suppression, and TULIP-2 met its primary clinical endpoint based on BICLA [6,22–24]. The U.S. approval followed the clinical evidence. The program shows how a biomarker can clarify whether the drug engaged the intended pathway while clinical outcomes establish patient benefit.

Conclusion

SLE development programs can use mouse models to investigate disease mechanisms, pharmacologically relevant NHP studies to characterize exposure and functional PD, and clinical trials to establish patient benefit. The translational plan should specify which biomarker can be measured at each step, what the measurement tells us and how it relates to target-organ outcomes.

HKeyBio’s seven mouse models, two cynomolgus models and supporting database give teams several ways to build that evidence for SLE and CLE. Single-cell sequencing, spatial transcriptomics and NHP-derived organ-on-chip systems may help connect blood biomarkers with changes in the cell populations and tissues that drive disease.

Author. HKeyBio Marketing Department

Editor. Jing Yan

About HKeyBio

HKeyBio is a preclinical contract research organization focused on autoimmune and allergic diseases, with end-to-end in vivo efficacy services. Its core technical team has more than 20 years of experience across autoimmune drug development. The ISO 9001-certified company operates molecular, cellular, pathology, small-animal and analytical facilities in Suzhou Industrial Park, with nonhuman primate study facilities in Suzhou and Guangxi. At the time of the original article, HKeyBio reported approximately 80 employees and master’s or doctoral qualifications among its project leads.

· 50+ nonhuman primate models of autoimmune and allergic disease

· 500+ animal models of autoimmune and allergic disease

· Experience supporting 500+ IND applications in autoimmune disease

Disclaimer. This article is provided for general information and offers no investment advice. Readers are responsible for their own investment decisions. HKeyBio makes no express or implied warranty as to the accuracy, reliability or completeness of this material. Please contact HKeyBio about any rights concerns so that we can review the material and remove it where appropriate.

References

[1] Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:1945–1961. Source

[2] Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus. Ann Rheum Dis. 2023;82:351–356. Source

[3] National Association of Chronic Disease Directors and Lupus Foundation of America. National Public Health Agenda for Lupus. Source

[4] Incidence and prevalence of systemic lupus erythematosus in urban China, 2013–2017: A nationwide population-based study. Sci Bull (Beijing). 2024. Source

[5] US Food and Drug Administration. Benlysta (belimumab) approval history. BLA 125370. Source

[6] US Food and Drug Administration. Saphnelo (anifrolumab-fnia) prescribing information. Revised April 2026. Initial U.S. approval 2021. Source

[7] US Food and Drug Administration. Gazyva (obinutuzumab) prescribing information. Lupus nephritis indication, 2025. Source

[8] Merrill JT, Neuwelt CM, Wallace DJ, et al. Rituximab in active systemic lupus erythematosus (EXPLORER). Arthritis Rheum. 2010;62:222–233. Source

[9] Rovin BH, Furie R, Latinis K, et al. Rituximab in active proliferative lupus nephritis (LUNAR). Arthritis Rheum. 2012;64:1215–1226. Source

[10] Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:271694. Source

[11] Yokogawa M, Takaishi M, Nakajima K, et al. Epicutaneous application of Toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice. Arthritis Rheumatol. 2014;66:694–706. Source

[12] Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J Immunol. 2004;172:2731–2738. Source

[13] Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay. MAbs. 2017. Source

[14] Martignoni M, Groothuis GMM, de Kanter R. Species differences in CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2:875–894. Source

[15] Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32:56–67. Source

[16] Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–730. Source

[17] Crow MK. Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82:999–1014. Source

[18] Aringer M, Costenbader K, Daikh D, et al. 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151–1159. Source

[19] Genetic factors in systemic lupus erythematosus: Contribution to disease phenotype. J Immunol Res. 2015. Source

[20] Qiao B, Wu J, Chu YW, et al. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford). 2005;44:1108–1114. Source

[21] Hypocomplementemia as a risk factor for organ damage accrual in patients with systemic lupus erythematosus. J Immunol Res. 2018. Source

[22] Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in SLE. Ann Rheum Dis. 2022;81:951–961. Source

[23] Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–221. Source

[24] Baker T, et al. Type I interferon blockade with anifrolumab in SLE: Gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. 2024. Source

[25] Chinese SLE Treatment and Research Group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with SLE. PLoS One. 2019;14:e0225516. Source

[26] Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in lupus nephritis, 1971–2015. Arthritis Rheumatol. 2016;68:1432–1441. Source

[27] Qu J, Yang F, Zhu T, et al. A reference single-cell regulomic and transcriptomic map of cynomolgus monkeys. Nat Commun. 2022;13:4069. Source

[28] Takahama S, Tomiyama T, Yoshio S, et al. Preclinical assessment of oral TLR7 agonist SA-5 in a nonhuman primate model. JCI Insight. 2025;10:e196809. Source

[29] Brown GJ, Cañete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022;605:349–356. Source

[30] Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency. Front Immunol. 2024. BioProject PRJNA1181153. Source

RELATED NEWS

HkeyBio is a China-based, globally-focused preclinical CRO dedicated exclusively to autoimmune and allergic diseases, with a unified service network across Asia, the Americas, Europe and Australia.

CONTACT US

Phone: +1 2396821165 / +86-512-67485716
Email: tech@hkeybio.com 
Suzhou HQ: 388 Xinping Street, Suzhou Industrial Park, Jiangsu, China 
Shanghai: 489 Yunchuan Road, Baoshan, Shanghai, China 
Nanning: Fazhan Avenue, Xixiangtang, Nanning, Guangxi, China 
Boston: 134 Coolidge Ave, Suite 2, Watertown, MA 02472, USA Melbourne: 432 St Kilda Rd, Melbourne, VIC 3004, Australia

QUICK LINKS

PRODUCTS CATEGORY

SIGN UP FOR OUR NEWSLETTER

Copyright © 2026 HkeyBio. All Rights Reserved.  Sitemap | Privacy Policy